Latest Insider Transactions at Chemomab Therapeutics Ltd. (CMMB)
This section provides a real-time view of insider transactions for Chemomab Therapeutics Ltd. (CMMB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Chemomab Therapeutics Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Chemomab Therapeutics Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jan 03
2023
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
336,900
-6.69%
|
$1,010,700
$3.93 P/Share
|
Jan 03
2023
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,100
-2.37%
|
$30,500
$5.03 P/Share
|
Jan 03
2023
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,700
-2.37%
|
$38,500
$5.03 P/Share
|
Nov 16
2022
|
Neil Harris Cohen Director |
SELL
Open market or private sale
|
Direct |
2,409
-19.41%
|
$4,818
$2.0 P/Share
|
Nov 16
2022
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
257,248
-50.0%
|
$514,496
$2.08 P/Share
|
Nov 16
2022
|
George Adi Mor Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
324,775
-50.0%
|
$649,550
$2.08 P/Share
|
May 24
2022
|
Joel Michael Maryles Director |
BUY
Open market or private purchase
|
Direct |
433
+12.24%
|
$866
$2.83 P/Share
|
May 18
2022
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
2,000
+13.88%
|
$6,000
$3.19 P/Share
|
Mar 18
2022
|
Joel Michael Maryles Director |
BUY
Open market or private purchase
|
Direct |
1,000
+41.67%
|
$4,000
$4.34 P/Share
|
Mar 16
2022
|
Donald Marvin Executive VP, CFO & COO |
BUY
Open market or private purchase
|
Direct |
500
+11.81%
|
$1,500
$3.28 P/Share
|
Mar 14
2022
|
Donald Marvin Executive VP, CFO & COO |
BUY
Open market or private purchase
|
Direct |
1,250
+26.86%
|
$5,000
$4.04 P/Share
|
Mar 14
2022
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
6,000
+19.71%
|
$24,000
$4.35 P/Share
|
Mar 14
2022
|
Dale R Pfost Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+35.94%
|
$7,500
$3.98 P/Share
|
Mar 11
2022
|
Nissim Darvish Director |
BUY
Open market or private purchase
|
Direct |
1,200
+50.0%
|
$4,800
$4.28 P/Share
|
Dec 06
2021
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
2,000
+31.21%
|
$14,000
$7.43 P/Share
|
Mar 16
2021
|
Neil Harris Cohen Director |
BUY
Open market or private purchase
|
Direct |
2,409
+50.0%
|
$98,769
$41.51 P/Share
|
Mar 16
2021
|
Peter Thiel > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
230,536
+17.22%
|
-
|
Mar 16
2021
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
288,170
+10.05%
|
$4,898,890
$17.35 P/Share
|